Exhibit 16.1
Thomas Leger and Co., L.L.P.
1235 North Loop West, Suite 907
Houston, Texas 77008
June 2, 2008
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C.
RE: Oncolin Therapeutics, Inc. – SEC File No. 000-50541
Dear Sir or Madam:
We have read Item 4.01 of the Form 8-K of Oncolin Therapeutics, Inc., dated May 22, 2008, and Item 4.01 of the amended Form 8-K/A of Oncolin Therapeutics, Inc. dated June 2, 2008 and agree with the statements concerning our firm made in the first, second, and third paragraphs of the amended Form 8-K. We have no basis to agree or disagree with other statements of the registrant contained in the Form 8-K or Form 8-K/A and, accordingly, make no comment on such statements.
Very truly yours,
/s/ Thomas Leger & Co. L.L.P.
Thomas Leger & Co. L.L.P.